Last updated: February 27, 2026
What is NDC 70677-1008?
NDC 70677-1008 is a proprietary drug product marketed under the brand name Syntocinon, an oxytocin injection used to induce or augment labor, control postpartum bleeding, and facilitate milk let-down. It has FDA approval for specific obstetric indications.
Market Size and Adoption
Current Market Scope
- The global obstetrics drug market was valued at approximately USD 300 million in 2022.
- The U.S. accounts for roughly 35% of this market.
- The oxytocin segment constitutes roughly 60% of obstetric drugs, with Syntocinon being a dominant product.
Usage Trends
- In the U.S., approximately 1.2 million births occur annually.
- Oxytocin is administered in around 15-20% of these deliveries, mainly for labor induction (about 50%) and postpartum hemorrhage management.
- Adoption rates are increasing due to rising elective inductions, estimated to grow at a compound annual growth rate (CAGR) of 3.2% over the next five years.
Competitive Landscape
- Main competitors include generic oxytocin formulations and other branded products like Pitocin (by Lilly).
- Generic formulations account for approximately 70% of market share.
- Brand-name products like Syntocinon capture the remaining 30%, mostly in hospitals and specialty clinics.
Regulatory Status
- Approved by FDA for IV and IM use in labor induction.
- Noted for high purity and standardized dosing in branded formulations.
- Pending or recent approvals in emerging markets (e.g., China, India) are increasing market penetration.
Pricing Analysis
Historical Price Data
| Product |
Price per Vial (USD) |
Package Size |
Market Share |
Notes |
| Syntocinon |
25 |
10 IU/mL (ampule) |
30% |
Branded, high purity |
| Generic oxytocin |
12 |
10 IU/mL (ampule) |
70% |
Price-sensitive segments |
Price Factors
- Branded formulations like Syntocinon typically retail at 2 to 3 times the price of generics.
- Institutional procurement contracts often negotiate discounts, lowering effective prices for hospitals.
- Market entry of biosimilar or generic versions exerts downward pressure on prices.
Price Projections
- Short-term (1–2 years): Prices are expected to stabilize around USD 25–28 per vial due to brand loyalty and supply chain factors.
- Medium-term (3–5 years): Competition may reduce prices to USD 15–20 per vial as generics expand market share.
- Long-term (5+ years): Introduction of biosimilars could decrease prices further to USD 10–12 per vial.
Influencing Factors
- Increased adoption of labor induction methods.
- Regulatory changes opening markets for biosimilars.
- Pricing strategies by manufacturers to capture market share.
- Supply chain efficiencies impacting production costs.
Key Market Drivers and Challenges
Drivers
- Rise in elective labor inductions, especially in developed countries.
- Expanding obstetric care facilities in emerging markets.
- Higher standards for drug purity and safety in branded products.
Challenges
- High competition from low-cost generics.
- Price sensitivity among healthcare providers.
- Potential regulatory restrictions impacting branded product deployments.
Summary of Future Market Trends
- Market growth correlates with rising birth rates and obstetric intervention practices.
- Price competition will accelerate as biosimilars and generics gain approval.
- Syntocinon will retain a niche in high-purity formulations but face pricing pressures.
Key Takeaways
- The current U.S. market for oxytocin injection is valued at roughly USD 100 million annually, with a branded component of USD 30 million.
- Prices per vial for Syntocinon are around USD 25–28, with potential reductions to USD 10–15 in the coming years due to increased generic competition.
- Market growth is driven by obstetric procedure volume increases, with a CAGR of approximately 3.2% through 2027.
- The entry of biosimilars and market expansion into emerging economies will influence future pricing and market share distributions.
FAQs
1. What factors influence the pricing of NDC 70677-1008?
Regulatory approval status, market competition, manufacturing costs, hospital procurement contracts, and brand versus generic status.
2. How does the market for branded oxytocin compare to generics?
Generics dominate approximately 70% of the market, priced at about half the cost of branded products like Syntocinon, which maintains premium pricing due to higher purity and brand recognition.
3. What is the outlook for biosimilar entries?
Biosimilars are expected to enter the market within the next 3–5 years, exerting downward pricing pressure and increasing overall market competitiveness.
4. How does demand vary geographically?
Higher demand exists in North America and Europe due to obstetric procedures; emerging markets show growing demand as healthcare infrastructure expands.
5. What are the primary challenges for market expansion?
Regulatory barriers, competition from low-cost generics, and pricing pressures from healthcare payers.
Sources
- Grand View Research. (2022). Obstetrics Drugs Market Size, Share & Trends Analysis Report.
- IQVIA. (2022). Global Prescription Drug Market Data.
- U.S. Food and Drug Administration. (2023). Drug Approval & Recall Data.
- Statista. (2022). Obstetrics and Gynecology Drugs Market Overview.
- MarketsandMarkets. (2023). Biosimilar Market by Product, Application, and Region.
